Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD
Sponsor: Department of Health, Executive Yuan, R.O.C. (Taiwan)
Listed as NCT01952756, this PHASE4 trial focuses on Peripheral Arterial Diseases and remains completed. Sponsored by Department of Health, Executive Yuan, R.O.C. (Taiwan), it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Department of Health, Executive Yuan, R.O.C. (Taiwan)
- National Cheng-Kung University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .